One vaccine dose enough for COVID-19 survivors


Two mRNA vaccines against COVID-19 have proven safe and effective in clinical trials, as well as in the millions of people who have been vaccinated so far. But how prior SARS-CoV-2 infection affects vaccine response, and how long that response lasts, are still uncertain. Now, a new study in ACS Nano supports increasing evidence that people who had COVID-19 need only one vaccine dose, and that boosters could be necessary for everyone in the future.

In clinical trials, the Pfizer-BioNTech and Moderna COVID-19 vaccines were about 95% effective in protecting against symptomatic infections. Both mRNA vaccines trigger the immune system to produce antibodies against the SARS-CoV-2 spike protein receptor binding domain (RBD), and two doses are necessary to provide immunity in people who haven’t previously had COVID-19.

However, the clinical trials included very few people who had already recovered from the disease, so the immune response of these individuals is less well known. Also, the time course of antibody development in both groups, and how long virus-neutralizing antibodies persist, haven’t been well characterized. So Otto Yang and colleagues wanted to compare antibody levels, quality and persistence after one and two doses of mRNA vaccine in people with or without prior SARS-CoV-2 infection.

The researchers used an enzyme-linked immunosorbent assay (ELISA) to measure antibodies against the RBD in people who received the Pfizer-BioNTech or Moderna vaccine, and in unvaccinated people soon after mild or severe COVID-19 cases. In the 28 participants without prior infection, one dose of either vaccine triggered antibody levels similar to those seen after mild COVID-19 infections, whereas two doses were required to obtain anti-RBD antibodies approaching those observed after severe cases.

Source: Read Full Article